Y-Biologics, Inc. (KOSDAQ: 338840)

South Korea flag South Korea · Delayed Price · Currency is KRW
7,230.00
-280.00 (-3.73%)
Dec 27, 2024, 9:00 AM KST
-53.65%
Market Cap 113.58B
Revenue n/a
Net Income n/a
Shares Out 14.77M
EPS n/a
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 39,979
Open 7,460.00
Previous Close 7,510.00
Day's Range 7,190.00 - 7,600.00
52-Week Range 6,400.00 - 19,200.00
Beta n/a
Analysts n/a
Price Target n/a
Earnings Date n/a

About Y-Biologics

Y-Biologics, Inc., an antibody new drug development platform company, engages in the research and development of immuno-oncology drugs and antibody drugs. It develops YBL-006, a PD-1 immune checkpoint inhibitor that is in clinical phase 1/2a medication for solid cancers. The company also develops mono-specific antibodies, such as YBL-011 and YBL-003 for solid cancers; YBL-013, an ALiCE antibody for solid cancers; and YBL-001, an anti-drug conjugate for small cell lung and liver cancers. Y-Biologics, Inc. was incorporated in 2007 and is headquar... [Read more]

Industry Biological Products, Except Diagnostic Substances
Founded 2007
Country South Korea
Stock Exchange KOSDAQ
Ticker Symbol 338840
Full Company Profile

News

There is no news available yet.